A Phase 2a, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects Who Have Chronic HCV-1/HIV-1 Co-Infection and Are Treatment-Naive for Hepatitis C.

Trial Profile

A Phase 2a, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects Who Have Chronic HCV-1/HIV-1 Co-Infection and Are Treatment-Naive for Hepatitis C.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2013

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Nov 2012 Final results (SVR24) were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
    • 23 Mar 2012 Actual patient number changed from 62 to 68 as reported by ClinicalTrials.gov.
    • 23 Mar 2012 Actual end date (1 Mar 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top